Please note that eDoc will be permanently shut down in the first quarter of 2021!      Home News About Us Contact Contributors Disclaimer Privacy Policy Help FAQ

Home
Search
Quick Search
Advanced
Fulltext
Browse
Collections
Persons
My eDoc
Session History
Login
Name:
Password:
Documentation
Help
Support Wiki
Direct access to
document ID:


          Institute: MPI für molekulare Biomedizin     Collection: Jahrbuch 2016 (publ. 2015, arch)     Display Documents



  history
ID: 717317.0, MPI für molekulare Biomedizin / Jahrbuch 2016 (publ. 2015, arch)
Receptor tyrosine kinase inhibitors: Are they real tumor killers?
Authors:Gaumann, A. K.; Kiefer, F.; Alfer, J.; Lang, S. A.; Geissler, E. K.; Breier, G.
Date of Publication (YYYY-MM-DD):2016-02-01
Title of Journal:Int J Cancer
Volume:138
Issue / Number:3
Start Page:540
End Page:554
Review Status:Internal review
Audience:Not Specified
Abstract / Description:Inhibiting tumor growth by targeting the tumor vasculature was first proposed by Judah Folkman almost 40 years ago. Since then, different approaches and numerous drugs and agents have been developed to achieve this goal, either with the aim of inhibiting tumor neoangiogenesis or normalizing the tumor vasculature. Among the most promising therapeutic targets are receptor tyrosine kinases (RTKs), some of which are predominantly expressed on tumor endothelial cells, although they are sometimes also present on tumor cells. The majority of RTK inhibitors investigated over the past two decades competes with ATP at the active site of the kinase and therefore block the phosphorylation of intracellular targets. Some of these drugs have been approved for therapy, whereas others are still in clinical trials. Here, we discuss the scientific basis, current status, problems and future prospects of RTK inhibition in anti-tumor therapy.
Free Keywords:VEGF receptor; receptor tyrosine kinase; small molecule inhibitor; tumor angiogenesis
External Publication Status:published
Document Type:Article
Communicated by:Keuker
Affiliations:MPI für molekulare Biomedizin
External Affiliations:Institute of Pathology, University of Regensburg, Medical Center, Regensburg, Germany. Mammalian Cell Signaling Laboratory, Max Planck Institute for Molecular Biomedicine, Munster, North Rhine-Westphalia, Germany. Department of Surgery, University of Regensburg, Medical Center, Regensburg, Germany. Institute of Pathology, Technical University Dresden, Dresden, Germany.
Identifiers:ISSN:1097-0215 (Electronic) 0020-7136 (Linking) %R 10.1... [ID No:1]
URL:http://www.ncbi.nlm.nih.gov/pubmed/25716346 [ID No:2]
The scope and number of records on eDoc is subject to the collection policies defined by each institute - see "info" button in the collection browse view.